Replies to post #108825 on Biotech Values

[genisi]

..."we consider it unlikely that a targeted biologic is increasing suicidality in a patient population already known to be at increased risk."

I would add that it is even more unlikely that a monoclonal antibody that is too big to pass through the BBB is increasing suicidality.